Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792463 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL14732611 | 0.83 | TDP1 (0.43) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL6742672 | 0.83 | BCL9 (0.50) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL3616763 | 0.82 | KDM4E (0.66) | KDM4EALDH1A1SMN1; SMN2MAOBBCHE | |
| SCHEMBL3616760 | 0.82 | KDM4E (0.66) | KDM4EALDH1A1SMN1; SMN2MAOBBCHE | |
| SCHEMBL23343626 | 0.81 | CYP3A4 (0.56) | KDM4EALDH1A1SMN1; SMN2KMT2AMAOB | |
| SCHEMBL1665199 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL6742049 | 0.80 | ALOX15 (0.51) | KDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL421378 | 0.79 | BCL9 (0.53) | KDM4EALDH1A1SMN1; SMN2PDGFRBPDGFRA | |
| SCHEMBL6742038 | 0.76 | TOP2A (0.59) | KDM4EALDH1A1SMN1; SMN2KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | KDM4E 1835/4885ALDH1A1 3196/4885SMN1; SMN2 2253/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | KDM4E 3842/4885ALDH1A1 863/4885SMN1; SMN2 1209/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | KDM4E 1803/4885ALDH1A1 3103/4885SMN1; SMN2 2272/4885 |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | KDM4E 787/4885ALDH1A1 342/4885SMN1; SMN2 3705/4885 |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | KDM4E 787/4885ALDH1A1 342/4885SMN1; SMN2 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.